Patents by Inventor Jens Rosengren Daugaard

Jens Rosengren Daugaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20190076506
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: May 22, 2018
    Publication date: March 14, 2019
    Inventors: Ditte RIBER, Eddi MEIER, Jens Rosengren DAUGAARD, Marie SKOVGAARD, Jakob Lind TOLBORG, Gita KAMPEN, Camilla Ærteberg BÆK
  • Acylated glucagon analogues
    Patent number: 10004786
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: June 26, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Eddi Meier, Jens Rosengren Daugaard, Marie Skovgaard, Jakob Lind Tolborg, Gita Kampen, Camilla Ærteberg Bæk
  • GLUCAGON ANALOGUES
    Publication number: 20160304576
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: June 27, 2016
    Publication date: October 20, 2016
    Inventors: Eddi MEIER, Ditte RIBER, Jens Rosengren DAUGAARD, Marie SKOVGAARD
  • Glucagon analogues
    Patent number: 9403894
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the glucagon-like peptide-1 (GLP-1) receptor as compared to human glucagon.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: August 2, 2016
    Assignee: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Jens Rosengren Daugaard, Marie Skovgaard
  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20160120951
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: September 2, 2015
    Publication date: May 5, 2016
    Inventors: Ditte RIBER, Eddi MEIER, Jens Rosengren DAUGAARD, Marie SKOVGAARD, Jakob Lind TOLBORG, Gita KAMPEN, Camilla Ærteberg BÆk
  • Acylated glucagon analogues
    Patent number: 9156901
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: October 13, 2015
    Inventors: Ditte Riber, Eddi Meier, Jens Rosengren Daugaard, Marie Skovgaard, Jakob Lind Tolborg, Gita Kampen, Camilla Ærteberg Bæk
  • GLUCAGON ANALOGUES
    Publication number: 20150080295
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: March 3, 2014
    Publication date: March 19, 2015
    Applicant: Zealand Pharma A/S
    Inventors: Eddi MEIER, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard
  • GLUCAGON ANALOGUES
    Publication number: 20140127175
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: January 7, 2014
    Publication date: May 8, 2014
    Inventors: Eddi MEIER, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard
  • Glucagon analogues
    Patent number: 8685919
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: April 1, 2014
    Assignee: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard
  • Glucagon analogues
    Patent number: 8680049
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: March 25, 2014
    Assignee: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup
  • Glucagon analogues
    Patent number: 8642541
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: February 4, 2014
    Assignee: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup
  • Glucagon analogues
    Patent number: 8642540
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: December 15, 2008
    Date of Patent: February 4, 2014
    Assignee: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard
  • GLUCAGON ANALOGUES
    Publication number: 20130157935
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: June 23, 2011
    Publication date: June 20, 2013
    Applicant: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Jens Rosengren Daugaard, Marie Skovgaard
  • ACYLATED GLUCAGON ANALOGUES
    Publication number: 20120178670
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes and associated metabolic disorders. In particular, the invention provides novel acylated glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: June 24, 2010
    Publication date: July 12, 2012
    Applicant: Zealand Pharma A/S
    Inventors: Ditte Riber, Eddi Meier, Jens Rosengren Daugaard, Marie Skovgaard, Jakob Lind Tolborg, Gita Kampen, Camilla Ærteberg Bæk
  • GLUCAGON ANALOGUES
    Publication number: 20110293587
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: December 15, 2008
    Publication date: December 1, 2011
    Applicant: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup
  • GLUCAGON ANALOGUES
    Publication number: 20110286981
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: December 15, 2008
    Publication date: November 24, 2011
    Applicant: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard, Trine Skovlund Ryge Neerup
  • GLUCAGON ANALOGUES
    Publication number: 20110286982
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metablic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: December 15, 2008
    Publication date: November 24, 2011
    Applicant: Zealand Pharma A/S
    Inventors: Eddi Meier, Ditte Riber, Marie Skovgaard, Bjarne Due Larsen, Jens Rosengren Daugaard
  • Glucagon analogues
    Patent number: 7994122
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain in a subject. In particular, the invention provides novel glucagon analogue peptides effective in such methods and in the treatment of obesity, eating disorders, metabolic syndrome, and non-alcoholic liver steatosis. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: August 9, 2011
    Assignee: Zealand Pharma A/S
    Inventors: Ditte Riber, Eddi Meier, Trine Skovlund Ryge, Jens Rosengren Daugaard
  • GLUCAGON ANALOGUES
    Publication number: 20100204105
    Abstract: The invention provides materials and methods for promoting weight loss or preventing weight gain in a subject. In particular, the invention provides novel glucagon analogue peptides effective in such methods and in the treatment of obesity, eating disorders, metabolic syndrome, and non-alcoholic liver steatosis. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
    Type: Application
    Filed: June 16, 2008
    Publication date: August 12, 2010
    Applicant: Zealand Pharma A/S
    Inventors: Ditte Riber, Eddi Meier, Trine Skovlund Ryge, Jens Rosengren Daugaard